|
HY-P99152-1mg
|
MedChemexpress LLC
|
Mu romonab [CAS 140608-64-6]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99152-10mg
|
MedChemexpress LLC
|
Mu romonab [CAS 140608-64-6]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99152-5mg
|
MedChemexpress LLC
|
Mu romonab [CAS 140608-64-6]
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240B-1mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (acetate)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240B-10mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (acetate)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240B-5mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (acetate)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1240A-1mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1240A-10mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1240A-5mg
|
MedChemexpress LLC
|
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (TFA)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P99235-1mg
|
MedChemexpress LLC
|
Nadunolimab
|
|
Cancer-programmed cell death
|
|
|
HY-P99235-10mg
|
MedChemexpress LLC
|
Nadunolimab
|
|
Cancer-programmed cell death
|
|
|
HY-P99235-5mg
|
MedChemexpress LLC
|
Nadunolimab
|
|
Cancer-programmed cell death
|
|
|
HY-112615-1mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 1 [CAS 2241019-57-6]
|
|
Cancer-programmed cell death
|
|
|
HY-112615-10mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 1 [CAS 2241019-57-6]
|
|
Cancer-programmed cell death
|
|
|
HY-112615-5mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 1 [CAS 2241019-57-6]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-10mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-100mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-25mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-5mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-50mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-P99376-1mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
|
HY-P99376-10mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
|
HY-P99376-5mg
|
MedChemexpress LLC
|
Narsoplimab [CAS 2108782-45-0]
|
|
COVID-19-anti-virus
|
|
|
HY-108831A-1mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
|
HY-108831A-10mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
